According to the arm Phase II study which comprised 126 patients receiving BIBF 1120 as first-line treatment in combination with mFOLFOX6 showed a median progression-free survival of 10.6
Under the deal, both the firms will focus on developing three of Proximagen’s programmes, with the aim of identifying novel innovative therapies for serious diseases such as epilepsy,
The grant allows both the companies to jointly develop a preclinical program on a potential new treatment for stroke patients. The program is aimed to deliver NeuroVive’s cyclosporin
The decision was made because Astellas found it was difficult to find a partner for the Phase III clinical development and commercialization of darexaban. The company also considered
The NoA includes claims directed to the use of Zertane with a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors commonly used for the treatment of ED
Additionally, Onyx has requested priority review of the application, which reduces the time the FDA takes to review a new drug application. Onyx Research and Development and Technical
Colesevelam, an orally administered, bile-acid sequestrant showed efficacy in reducing LDL-C lipoproteins and drug-interaction and tolerability profile comparable to placebo. Valeant chairman and CEO Michael Pearson said clinical
The MycoDiverse library is a collection of 10,000 refined fractions from fermentations of higher fungi, developed using the company’s technology to stimulate secondary metabolite production. The collection is
The trial aims to investigate the safety and tolerability of YM’s JAK1/JAK2 inhibitor, as well as its efficacy in reducing spleen size, improving constitutional symptoms and reducing transfusion
The company said there are no therapies for patients with LAL Deficiency. However, SBC-102 can possibly be a disease modifying long-term enzyme replacement therapy for patients including infants,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.